XML 106 R83.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Oct. 31, 2021
Oct. 21, 2021
Subsidiary or Equity Method Investee [Line Items]          
Common stock, shares authorized 100,000,000 100,000,000 144,406,928   100,000,000
Aggregate intrinsic value of common stock exercised   $ 1.8      
Fair value of options vested   $ 6.0 $ 0.6    
Weighted average grant date fair value   $ 8.18 $ 0.37    
Unrecognized stock-based compensation expense $ 8.9 $ 8.9      
Repurchase of common stock   0 0    
Shares subject to repurchase   377,709 136,032    
Aggregate exercise prices of early exercised shares   $ 0.2 $ 0.1    
Common stock, par value $ 0.001 $ 0.001 $ 0.001 $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000 0   5,000,000
Preferred stock, par value $ 0.001 $ 0.001 $ 0.001   $ 0.001
Unrecognized stock-based compensation expense, weighted-average recognition period   2 years 7 months 6 days      
Common stock, shares reserved for issuance 1,934,095 1,934,095 67,065    
Dividend yield   0.00% 0.00%    
Restricted Stock Units          
Subsidiary or Equity Method Investee [Line Items]          
Granted   394,750      
Unrecognized stock-based compensation expense $ 1.9 $ 1.9      
Unrecognized stock-based compensation expense, weighted-average recognition period   1 year      
ESPP          
Subsidiary or Equity Method Investee [Line Items]          
Number of shares authorized for offerings 0 0      
Common stock, shares reserved for issuance       401,164  
2008 Stock Plan          
Subsidiary or Equity Method Investee [Line Items]          
Share-based Compensation arrangement by share-based payment award, award vesting period   10 years      
Share based compensation arrangement by share based payment award ratably thereafter vesting period   36 months      
Percentage of vesting rights   25.00%      
Vesting period   1 year      
2021 Plan          
Subsidiary or Equity Method Investee [Line Items]          
Share-based Compensation arrangement by share-based payment award, award vesting period   10 years      
Share based compensation arrangement by share based payment award ratably thereafter vesting period   36 months      
Percentage of vesting rights   25.00%      
Vesting period   1 year      
Granted 394,750        
Maximum [Member]          
Subsidiary or Equity Method Investee [Line Items]          
Aggregate intrinsic value of common stock exercised     $ 0.1    
Incremental compensation cost     $ 0.1    
Maximum [Member] | 2008 Stock Plan          
Subsidiary or Equity Method Investee [Line Items]          
Exercise price, percent of estimated fair value of shares on date of grant   110.00%      
Exercise price, percent of estimated fair market value of shares on date of grant   100.00%      
Maximum [Member] | 2021 Plan          
Subsidiary or Equity Method Investee [Line Items]          
Exercise price, percent of estimated fair value of shares on date of grant   110.00%      
Exercise price, percent of estimated fair market value of shares on date of grant   100.00%      
Minimum | 2008 Stock Plan          
Subsidiary or Equity Method Investee [Line Items]          
Estimated fair value shares date of grant   10.00%      
Minimum | 2021 Plan          
Subsidiary or Equity Method Investee [Line Items]          
Estimated fair value shares date of grant   10.00%